This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Quillivant, NWP06, methylphenidate extended-release suspension, QuilliChew ER
NWP06 is a novel extended-release liquid methylphenidate, developed using Tris’ OralXR+ platform.
The exact mechanism of action in ADHD is unknown. The drug is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into synapses.
Quillivant was developed by NextWave Pharmaceuticals in collaboration with Tris Pharma, the company's technology and manufacturing partner.
NextWave and Pfizer
In October 2012, Pfizer exercised its option to acquire NextWave. Under the terms of the agreement, Pfizer will make a payment to of $255 million to NextWaves shareholders at the closing of the transaction, and NextWaves shareholders are eligible to receive additional payments of up to $425 million based on certain sales milestones.
In November 2012, Pfizer completed its acquisition of NextWave.
Partners: Tris Pharma
Quillivant XR News
Pink Sheet Pfizer To Purchase NextWave For ADHD Drug
Additional information available to subscribers only: